<DOC>
	<DOCNO>NCT00151255</DOCNO>
	<brief_summary>This study look all-trans retinoic acid combination standard induction consolidation therapy old patient newly diagnose acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>All-Trans Retinoic Acid Combination With Standard Induction Consolidation Therapy Older Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>First Induction Therapy : - Cytarabine 100 mg/m² cont . i.v . day 1-5 - Idarubicin 12 mg/m² i.v . day 1 , 3 - ATRA 45 mg/m² p.o . day 4-6 , ATRA 15 mg/m² p.o . day 7-28 Second Induction Therapy : - Cytarabine 100 mg/m² cont . i.v . day 1-5 - Idarubicin 12 mg/m² i.v . day 1 , 3 - ATRA 45 mg/m² p.o . day 4-6 , ATRA 15 mg/m² p.o . day 7-28 First Consolidation Therapy : - Cytarabine 1000 mg/m² bid i.v . day 1-3 - Mitoxantrone 10 mg/m² i.v . day 2 , 3 - ATRA 15 mg/m² p.o . day 4-28 Second Consolidation Therapy - Etoposide 100 mg/m² i.v . day 1-5 - Idarubicin 12 mg/m² i.v . day 1,3 - ATRA 15 mg/m² p.o . day 4-28</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Newly diagnose AML define accord World Health Organization ( WHO ) classification ( exclude acute promyelocytic leukemia [ APL ] ) Aged &gt; 60 year All patient inform character study . Written informed consent patient study entry . Molecular cytogenetical analysis initial bone marrow peripheral blood specimen perform central reference laboratory . Bleeding independent AML Acute promyelocytic leukemia Uncontrolled infection Participation concurrent clinical study Insufficiency kidney ( creatinine &gt; 1.5 x upper normal serum level ) , liver ( bilirubin , AST AP &gt; 2 x upper normal serum level ) , severe obstruction restrictive ventilation disorder , heart failure New York Heart Association [ NYHA ] III/IV Severe neurological psychiatric disorder interfere ability give informed consent No consent registration , storage processing data concern characteristic AML individual course Performance status WHO &gt; 2</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>age &gt; 60 year</keyword>
</DOC>